Phaseline

Targets › IGM

IGM: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Respiratory; next expected readout Jul 2028.

Open in Phaseline: the race on IGM, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
BiotestTrimodulin (BT588)
Polyclonal immunoglobulin preparation (IgG, IgM, IgA)
IGG, IGM, IGAPhase 3Community-acquired PneumoniaJul 2028

Conditions

Community-acquired Pneumonia (1)

Modalities

small molecule (1)

Companies

Biotest (1)

Related targets

IGG (1) IGA (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.